Federal Register / Vol. 71, No.
231 / Friday, December 1, 2006 / Notices 69593
this is notice that on September 6, 2006,
National Center for Natural Products
Research-NIDA MProject, University of
Mississippi, 135 Coy Waller Lab
Complex, University, Mississippi 38677,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in
schedules I:
Drug
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
The company plans to cultivate
marihuana for the National Institute of
Drug Abuse for research approved by
the Department of Health and Human
Services.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than January 30, 2007.
Dated: November 21, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–20342 Filed 11–30–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 22,
2006, Norac, Inc., 405 S. Motor Avenue,
P.O. Box 577, Azusa, California 91702,
rmajette on PROD1PC67 with NOTICES1
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Tetrahydrocannabinols
(7370), a basic class of controlled
substance listed in schedule I.
VerDate Aug<31>2005 13:50 Nov 30, 2006 Jkt 211001
The company plans to manufacture
the listed controlled substance in bulk
for formulation into the pharmaceutical
controlled substance Marinol.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
Schedule should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
I Office of Diversion Control, Drug
I Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than January 30, 2007.
Dated: November 21, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–20340 Filed 11–30–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on June 27, 2006,
Noramco Inc., 1440 Olympic Drive,
Athens, Georgia 30601, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Oxymorphone (9652), a basic class of
controlled substance listed in schedule
II.
The company plans to manufacture
for in-house dosage form production
and for sales to other dosage form
manufacturers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
PO 00000 Frm 00065 Fmt 4703 Sfmt 4703
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Representative/ODL, 2401
Jefferson-Davis Highway, Alexandria,
Virginia 22301; and must be filed no
later than January 30, 2007.
Dated: November 21, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–20341 Filed 11–30–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 20,
2006, Organix Inc., 240 Salem Street,
Woburn, Massachusetts 01801, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Cocaine (9041), a basic class of
controlled substance listed in schedule
II.
The company plans to manufacture a
chemical that is a derivative of cocaine
that will be sold to their customer for
research purposes.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than January 30, 2007.
Dated: November 21, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–20332 Filed 11–30–06; 8:45 am]
BILLING CODE 4410–09–P
E:\FR\FM\01DEN1.SGM 01DEN1